RT Generic
T1 Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature
A1 Delgado-Fernandez, Marcial
A1 Garcia-Gemar, Gracia Mar
A1 Fuentes-Lopez, Ana
A1 Munoz-Perez, Manuel Isidro
A1 Oyonarte-Gomez, Salvador
A1 Ruiz-Garcia, Ignacio
A1 Martin-Carmona, Jessica
A1 Sanz-Canovas, Jaime
A1 Castano-Carracedo, Manuel Aangel
A1 Reguera-Iglesias, Jose Maria
A1 Ruiz-Mesa, Juan Diego
K1 Covid-19
K1 Convalescent plasma
K1 Humoral immunodeficiency
K1 Rituximab
K1 Obinutuzumab
K1 Coronavirus disease 2019
K1 Liver-transplant recipients
K1 Rituximab
K1 Sars-cov-2
K1 Therapy
K1 Antibodies
K1 Mechanism
K1 Outcomes
AB Patients lacking humoral response have been suggested to develop a less severe COVID-19, but there are some reports with a prolonged, relapsing or deadly course. From April 2020, there is growing evidence on the benefits of COVID-19 convalescent plasma (CCP) for patients with humoral immunodeficiency. Most of them had a congenital primary immunodeficiency or were on treatment with anti CD20 antibodies. We report on three patients treated in our hospital and review thirty-one more cases described in the literature. All patients but three resolved clinical picture with CCP. A dose from 200 to 800 ml was enough in most cases. Antibody levels after transfusion were negative or low, suggesting consumption of them in SARS-CoV-2 neutralization. These patients have a protracted clinical course shortened after CCP. CCP could be helpful for patients with humoral immunodeficiency. It avoid relapses and chronification. CCP should be transfused as early as possible in patients with COVID-19 and humoral immunodeficiency.(c) 2021 Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica. Published by Elsevier Espana, S.L.U. All rights reserved.
PB Ediciones doyma s a
SN 0213-005X
YR 2022
FD 2022-11-01
LK https://hdl.handle.net/10668/26025
UL https://hdl.handle.net/10668/26025
LA en
DS RISalud
RD Apr 18, 2025